Cellectis S.A. (ALCLS.PA)
EUR 1.35
(0.15%)
EUR 1.35
(0.15%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -2.08 USD | 18.43% |
| 2022 | -2.17 USD | -12.44% |
| 2021 | -1.93 USD | -12.87% |
| 2020 | -1.71 USD | 20.09% |
| 2019 | -2.14 USD | -10.88% |
| 2018 | -1.93 USD | 30.58% |
| 2017 | -2.78 USD | -53.59% |
| 2016 | -1.81 USD | -174.24% |
| 2015 | -0.66 USD | -73433.33% |
| 2014 | 0.00 USD | 100.02% |
| 2013 | -4.08 USD | -175.68% |
| 2012 | -1.48 USD | 32.42% |
| 2011 | -2.19 USD | -188.16% |
| 2010 | -0.76 USD | -94.87% |
| 2009 | -0.39 USD | -3077.1% |
| 2008 | 0.01 USD | 104.23% |
| 2007 | -0.31 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | 0.08 USD | 112.12% |
| 2024 Q2 | -0.28 USD | -450.0% |
| 2023 Q3 | -0.31 USD | -63.16% |
| 2023 FY | - USD | 18.43% |
| 2023 Q4 | -0.66 USD | -112.9% |
| 2023 Q1 | -0.58 USD | -1.75% |
| 2023 Q2 | -0.19 USD | 67.24% |
| 2022 Q4 | -0.57 USD | -3.64% |
| 2022 Q1 | -0.69 USD | 31.0% |
| 2022 FY | - USD | -12.44% |
| 2022 Q2 | -0.10 USD | 86.1% |
| 2022 Q3 | -0.55 USD | -473.51% |
| 2021 Q3 | -0.82 USD | 6.82% |
| 2021 Q2 | -0.88 USD | -214.29% |
| 2021 Q4 | -1.00 USD | -21.95% |
| 2021 FY | - USD | -12.87% |
| 2021 Q1 | -0.28 USD | 70.53% |
| 2020 FY | - USD | 20.09% |
| 2020 Q1 | 0.47 USD | 153.41% |
| 2020 Q2 | -0.76 USD | -261.7% |
| 2020 Q3 | -0.71 USD | 6.58% |
| 2020 Q4 | -0.95 USD | -33.8% |
| 2019 Q2 | -0.79 USD | -119.44% |
| 2019 Q3 | -0.38 USD | 51.9% |
| 2019 FY | - USD | -10.88% |
| 2019 Q1 | -0.36 USD | 33.33% |
| 2019 Q4 | -0.88 USD | -131.58% |
| 2018 FY | - USD | 30.58% |
| 2018 Q4 | -0.54 USD | 0.0% |
| 2018 Q3 | -0.54 USD | -217.65% |
| 2018 Q2 | -0.17 USD | 76.06% |
| 2018 Q1 | -0.71 USD | 6.58% |
| 2017 Q3 | -0.73 USD | 6.41% |
| 2017 Q4 | -0.76 USD | -4.11% |
| 2017 FY | - USD | -53.59% |
| 2017 Q2 | -0.78 USD | -39.29% |
| 2017 Q1 | -0.56 USD | -51.35% |
| 2016 Q2 | -0.20 USD | 78.95% |
| 2016 Q4 | -0.37 USD | 7.5% |
| 2016 Q3 | -0.40 USD | -100.0% |
| 2016 FY | - USD | -174.24% |
| 2016 Q1 | -0.95 USD | -480.0% |
| 2015 Q2 | -0.71 USD | -422.73% |
| 2015 FY | - USD | -73433.33% |
| 2015 Q1 | 0.22 USD | 46.67% |
| 2015 Q4 | 0.25 USD | 160.98% |
| 2015 Q3 | -0.41 USD | 42.25% |
| 2014 Q1 | -0.14 USD | 62.16% |
| 2014 FY | - USD | 100.02% |
| 2014 Q4 | 0.15 USD | -6.25% |
| 2014 Q3 | 0.16 USD | 260.97% |
| 2014 Q2 | -0.10 USD | 29.0% |
| 2013 Q3 | -0.36 USD | 23.4% |
| 2013 Q4 | -0.37 USD | -2.78% |
| 2013 FY | - USD | -175.68% |
| 2013 Q1 | -0.46 USD | -91.67% |
| 2013 Q2 | -0.47 USD | -2.17% |
| 2012 Q4 | -0.24 USD | 25.0% |
| 2012 FY | - USD | 32.42% |
| 2012 Q3 | -0.32 USD | 0.0% |
| 2011 FY | - USD | -188.16% |
| 2010 FY | - USD | -94.87% |
| 2009 FY | - USD | -3077.1% |
| 2008 FY | - USD | 104.23% |
| 2007 FY | - USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| ABIONYX Pharma SA | -0.12 EUR | -1633.333% |
| ABIVAX Société Anonyme | -3.43 EUR | 39.359% |
| Adocia SA | -1.91 EUR | -8.901% |
| Aelis Farma SA | -0.39 EUR | -433.333% |
| Biophytis S.A. | -12.55 EUR | 83.426% |
| Advicenne S.A. | -0.67 EUR | -210.448% |
| genOway Société anonyme | 0.17 EUR | 1323.529% |
| IntegraGen SA | -0.03 EUR | -7930.888% |
| Medesis Pharma S.A. | -0.80 EUR | -160.0% |
| Neovacs S.A. | -0.00 EUR | -83100.0% |
| NFL Biosciences SA | -0.46 EUR | -352.174% |
| Plant Advanced Technologies SA | 0.07 EUR | 3071.429% |
| Quantum Genomics Société Anonyme | -0.09 EUR | -2185.714% |
| Sensorion SA | -0.17 EUR | -1123.529% |
| Theranexus Société Anonyme | -0.88 EUR | -136.364% |
| TME Pharma N.V. | -1.34 EUR | -55.224% |
| Valbiotis SA | -0.59 EUR | -252.542% |
| TheraVet SA | -0.49 EUR | -324.49% |
| Valerio Therapeutics Société anonyme | -0.15 EUR | -1286.667% |
| DBV Technologies S.A. | -0.71 EUR | -192.958% |
| Genfit S.A. | -0.58 EUR | -258.621% |
| GeNeuro SA | -0.59 EUR | -252.542% |
| Innate Pharma S.A. | -0.09 EUR | -2110.414% |
| Inventiva S.A. | -2.43 EUR | 14.403% |
| MaaT Pharma SA | -1.73 EUR | -20.231% |
| MedinCell S.A. | -0.88 EUR | -136.364% |
| Nanobiotix S.A. | -1.08 EUR | -92.593% |
| OSE Immunotherapeutics SA | -1.18 EUR | -76.271% |
| Poxel S.A. | -0.91 EUR | -128.571% |
| GenSight Biologics S.A. | -0.54 EUR | -285.185% |
| Transgene SA | -0.22 EUR | -845.455% |
| Valneva SE | -0.73 EUR | -184.932% |